Objective: Our goal was to determine the role of nitric oxide (NO) on the coronary vasodilation induced by prostacyclin (PGI,) in conscious dogs. Methods: Dogs were chronically instrumented for the measurements of coronary blood flow (CBF), left ventricular pressure (LVP), mean arterial pressure (MAP) and heart rate (HR). Results: Intravenous injections of PGI, caused dose-dependent increases in CBF, and decreases in MAP and late diastolic coronary resistance (LDCR). For instance, CBF increased by 128 f 19% (P < 0.05) from 30 * 3.5 ml/min and LDCR decreased by 73 f 3% (P < 0.05) from 2.57 f 0.20 mmHg/ml/min following injection of PGI, (1 .O pg/kg). After infusion of nitro-L-arginine (NLA, 35 mg/kg) intravenously, the coronary vasodilation induced by PGI, was partially attenuated. PGI, (1.0 pg/kg) increased CBF by 55 f 15% from 33 f 5.3 ml/min and decreased LDCR by 42 + 9% (both P < 0.05, compared with before NLA) from 3.29 + 0.39 mmHg/ml/min. Infusion of L-arginine (100 mg/kg) reversed the action of NLA. For example, PGI, (1.0 pg/kg) increased CBF by 115 + 15% from 36 f 6 ml/min and decreased LDCR by 68 f 3% from 3.02 & 0.36 mmHg/ml/min (both P > 0.05, compared with before NLA). Atropine (0.1 mg/kg) partially attenuated the coronary vasodilation induced by PGI, the magnitude of which was almost identical to that by NLA. NLA or atropine also blunted the coronary vasodilation induced by acetylcholine, while the coronary vasodilation induced by nitroglycerin was not affected by NLA. Conclusion: Our results indicate that the coronary vasodilation induced by PGI, was partially attenuated by NLA or atropine, suggesting that the coronary vasodilation induced by PGI, is due to two components: a reflex parasympathetic cholinergic vasodilation mediated by NO and a direct action of PGI,.
Introduction
In recent years, endothelial cells have been recognized as an important multifunctional cell type playing an essential role in cardiovascular homeostasis and in regulation of circulating vasoactive compounds [l-5] . Endothelial cells produce vasodilators and vasoconstrictors [l] . Two of the most important vasodilators are nitric oxide (NO) and prostacyclin (PGI,). Nitric oxide is synthesized from the amino acid, L-arginine, by a family of enzymes [1, 2] . PGI, is the predominant metabolite of arachidonic acid metabolism by cyclooxygenase in vascular tissues [6, 7] . In vitro, PGI, directly relaxes a variety of vascular preparations , whereas in vivo PGI, causes hypotension and coronary vasodilation [ 1 1 -151. Our previous studies have shown that PGI, causes coronary vasodilation [16] and evokes a Bezold-Jarisch-like vagal reflex [17] .
Recently, we have found that parasympathetic cholinergic coronary vasodilation induced by carotid chemoreflex activation by nicotine or vagal stimulation is mediated by NO, as evidenced by significantly attenuated coronary vasodilation after administration of NL,A [18] . ln addition, we have found that the classical Bezold-Jarisch reflex coronary vasodilation following veratrine injection in conscious dogs is mediated almost entirely by NO [19] . From these studies Time for primary review 26 days. Research 32 C.1996) [940] [941] [942] [943] [944] [945] [946] [947] [948] we proposed that NO might play an important role in all forms of parasympathetic coronary vasodilation.
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Since PGI, can activate a cardiac vagal reflex [17] , it is unclear whether the coronary vasodilation after administration of PGI, is mediated by an NO mediated mechanism. The goal of this study was to determine the effects of NLA, one of the inhibitors of NO, on the coronary vasodilation following administration of PGI,.
College and conform to the Guiding Principles for the Use and Care of Laboratory Animals of the National Institutes of Health and the American Physiological Society.
Recording techniques
Whereas the direct actions of PGI, are generally mediated by intracellular CAMP accumulation, the cellular actions of NO are mediated by accumulation of cGMP. These two systems have been shown to be synergistic in the regulation of platelet aggregation 131. In addition, changes in blood flow velocity and shear rate by PGI, may release NO. Because PGI, is an endogenous stimulator of cardiac chemical receptors and thereby elicits cholinergic reflex coronary vasodilation and because cholinergic vasodilation in the heart is mediated by NO, we hypothesized that PGI, and NO may interact in vivo in a new and unique way in the control of the coronary circulation. If this is true, and NO production by coronary blood vessels is altered after heart failure or myocardial infarction, a time during which cardiac receptor reflexes have enhanced importance, this may be one of mechanisms responsible for a marked alteration in coronary vascular control in human disease.
Methods
Arterial pressure was measured by connecting the previously implanted catheter to strain-gauge transducer (Statham P23 ID, Newark, NJ) and mean arterial pressure (MAP) was derived using a 2 Hz low-pass filter. Left ventricular systolic pressure (LVSP) was measured from the solid-state pressure gauge, and the first derivative of left ventricular pressure with time (LV dP/dt) was calculated using a microprocessor set as a differentiator and having a frequency response flat to 7OOHz (National Semiconductor LM 324, Edison, NJ). Left circumflex coronary blood flow was measured from the previously placed ultrasonic flow transducer using a pulsed Doppler flowmeter (System 6, Triton Technology, San Diego, CA), and mean coronary blood flow was derived using a 2 Hz low pass filter. Late diastolic coronary resistance (LDCR) was chosen as the index of coronary vascular resistance since it is independent of the compressive effect of ventricular contraction on coronary microvessels and was calculated as the quotient of late diastolic arterial blood pressure and coronary blood flow 120,211. Heart rate was monitored from the pressure pulse interval using a cardiotachometer (Beckman Instruments, Newark, NJ).
Surgical preparation 2.3. Experimental protocols
Fourteen mongrel dogs (weighing 21-31 kg) were premedicated with Acepromazine (0.3 mg/kg, i.m.) and anesthetized with sodium pentobarbital (25 mg/kg, i.v), then intubated and ventilated with room air. A thoracotomy was performed in the left fifth intercostal space using sterile surgical techniques. Tygon catheters (Cardiovascular Instruments, Wakefield, MA) were placed in the descending thoracic aorta and in the left atria1 appendage for the measurement of pressures. A solid-state pressure gauge (P 6.5, Konigsberg Instruments, Pasadena, CA) was placed in the apex of the left ventricle for the measurement of left ventricular systolic (LVP) and diastolic pressure (LVEDP), and derivation of LV dP/dt. A Doppler flow transducer (Parks Medical Electronics, Beaverton, OR) was placed on the left circumflex coronary artery for the measurement of coronary blood flow (CBF). The chest was closed in layers. The wires and the catheters were run subcutaneously and exited from the back of the dog's neck. On the day of the experiment, with the dog lying on the laboratory table quietly, when the hemodynamic parameters and CBF were stable, the experiments were begun. The following drugs were administrated intravenously: (1) acetylcholine (ACh) at doses of 0.5, 5 and 10 pg/kg; (2) prostacyclin (PGI,) at doses of 0.1, 0.25, 0.5 and 1 .O Kg/kg; and (3) nitroglycerin (NTG) at a dose of 25 kg/kg. The drugs were given randomly and each measured variable was allowed to return to control for at least 10 min before the next drug was given. The dogs were allowed lo-14 days to recover fully and were trained to lie quietly on the laboratory table. On the day of the experiment, an intravenous catheter was inserted in a peripheral vein and attached to an infusion line for remote administration of drugs, To assess the effects of NLA on the responses to ACh, PGI,, and NTG, NLA (35 mg/kg) was infused, 30 min later the drugs were injected again. After that L-arginine (100 mg/kg) was infused and one dose of PGI, (1.0 kg/kg) was given again. Acetylcholine, arachidonic acid, atropine methyl bromide, L-arginine and propranolol were purchased from Sigma (St. Louis, MO). Nitro-L-arginine was obtained from Aldrich (Milwaukee, WI>. PGI, was bought from Cayman (Ann Arbor, MI).
Data analysis
All data are presented as mean + s.e.m. The responses are the peak responses after administration of each vasodilator. The statistical significance of differences was determined with paired t-test for each peak response, and multiple comparisons were evaluated with analysis of variance. The ratio of F values was converted to a t-distribution using a Scheffe's test. Significant changes were considered at the P < 0.05 level. 186 * 28% (P < 0.05) from 32 f 2.7 ml/min, respectively, and LDCR decreased by 50 f 6.5%, 71 f 2.6% and 73 f 3.0% (P < 0.05) from 2.34 f 0.22 mmHg/ml/min. ACh also decreased MAP and LVSP, and increased heart rate (I-W) and LV dP/dt. MAP decreased by 16 f 4, 31 f 4 and 35 f 4 mmHg; LVP was reduced by 11 + 3, 24*3 and 18f2 mmHg; HR increased by 63+ 11, 112 +_ 6 and 111 f 7 beats/min; LV dP/dt increased by 379 + 114, 469 &-95 and 555 f 115 mmHg/s.
Effects of PGI,
An example of the effects of PGI, on CBF and arterial pressure is shown in Fig. 1 . Bolus intravenous injection of PGI, caused dose-dependent elevation in CBF and reduction in LDCR. The actual changes are shown in Fig. 2 . Following administration of PGI, at doses of 0.1,0.25,0.5 and 1 .O pg/kg, CBF increased by 40 f 6.1, 70 f 12, 106 f 12 and 128 f 19% (all P < 0.05) from 30 f 3.5 ml/mm, respectively, and LDCR decreased by 34 f 5.4, 52 f 4.9, 67 f 3.2 and 73 + 3.0% (all P < 0.05) from 2.57 f 0.20 mmHg/ml/min (Fig. 3) . PGI, also resulted in dose-dependent decreases in MAP, LVP and LV dP/dt (Table 1) . MAP fell by 18 + 3, 33 + 5, 50 f 5 and 57 f 3 mmHg (all P < 0.05) from 97 f 3 mmHg; LVP decreased by12~3,19f2,33f4and35f2mmHg(allP<0.05) from 128 f 2 mmHg; LV dP/dt was reduced by 151 f 66, 405 f 78,621 f 130 and 773 f 50 mmHg/s from 2732 f 92. The changes in HR were dose-independent and modest. HR increased by 17 f 3, 33 f 5, 33 f 7 and 32 +_ 5 beats/min (all P < 0.05) from 75 + 8 beats/min.
Eftects of nitroglycerin
Nitroglycerin (25 pg/kg) increased CBF by 202 f 40% (P < 0.05) from 34 f 5.0 ml/min and decreased LDCR by 68 + 5.4% (P < 0.05) from 2.34 mmHg/ml/min. NTG also reduced MAP (27 f 3 mmHg, P < 0.05) and LVP (21 f 5 mmHg, P < 0.051, and increased HR (122 f 12 beats/min, P < 0.05) and LV dP/dt (1447 & 129 mmHg/s, P < 0.05). Values are mean f s.e.m., n = 6. * P < 0.05, compared with baseline; + P < 0.05, compared with control. mmHg/ml/min), however, these changes were not statistically significant. NLA significantly attenuated the coronary vascular and hemodynamic responses to intravenous injections of ACh. After NLA, the elevations in CBF and the reductions in LDCR were significantly smaller (all P < 0.05, compared with before NLA) following administration of ACh as shown in Fig. 3 . The decreases in MAP induced by ACh in doses of 0.5, 5 and 10 pg/kg were 5 f 2, 10 + 4 and 21 f 4 mmHg (all P < 0.05, compared with before NLA), and increases in HR by ACh were 5 f 5, 25 f 14 (both P < 0.05 compared with before NLA) and 65 f 22 beats/min (P > 0.05, compared with before NLA). The increases in LV dP/dt were 78 f 71, 121 f 77 and 203 +_ 97 mmHg/s (all P < 0.05, compared with before NLA), while the reductions in LVP were not altered by NLA (Table 1) .
NLA also attenuated the coronary vascular responses to PGI,. After infusion of NLA (35 mg/kg), the increases in CBF and the decreases in LDCR induced by PGI, were significantly different. The changes in CBF and LDCR induced by PGI, before and after NLA are summarized in Fig. 2 . The hemodynamic responses to PGI, were not altered by NLA (Table 1) L-Arginine could not reverse the hemodynamic effects of NLA, however, it reversed the impairment of the coronary vasodilator action of PGI, induced by NLA. After infusion of L-arginine (100 mg/kg), PGI, (1.0 pg/kg) increased CBF by 115 + 15% from 36 + 6ml/min, and reduced LDCR by 68 f 3% from 3.02 f 0.36 mmHg/ml/min (P > 0.05, compared to the control).
NLA did not influence the coronary vasodilation responses to NTG. After NLA, NTG still resulted in significant increases in CBF by 71 f 16 ml/min (202 &-37%) and decreases in LDCR by 72 f 3%. The reduction of MAP and LVP induced by NTG were not altered by NLA, whereas the elevation of HR and LV dP/dt were signifi- After infusion of indomethacin (10 mg/kg), baseline CBF, baseline LDCR and the hemodynamic parameters were not significantly altered (Table 2) .
Indomethacin attenuated significantly the coronary vascular and the hemodynamic responses to intravenous injection of AA. AA initially increased CBF by 230 IJI 14% and decreased LDCR by 76 f 1.4%. After administration of indomethacin (10 mg/kg), AA (1000 pg/kg) only increased CBF by 6.2 + 3.2 ml/min (14 f 6.7%) and decreased LDCR by 18 f 8.8% (both P > 0.05, compared to baseline). There were no significant changes in MAP, HR, LVP and LV dP/dt following injection of AA after indomethacin (Table 2 ). This indicates that indomethacin blocked prostaglandin synthesis.
Indomethacin did not change the coronary vasodilation nor the hemodynamic responses to intravenous injection of ACh (5 pug/kg). Before and after administration of indomethacin, the increases in CBF induced by ACh were 58 f 8 (204 f 18%) and 50 f 11 (170 f 17%) ml/min (P > 0.05) from 28 f 2.4 and 29 + 3.8 ml/min, and the decreases in LDCR were 76 f 1.98% and 73 f 1.44% (P > 0.05) from 2.48 f 0.10 and 2.61 f 0.30 mmHg/ml/min (Fig. 3) . The changes in MAP, HR, LVP and LV dP/dt induced by ACh were not influenced by indomethacin (Table 2) .
Indomethacin did not affect the coronary vasodilation and the hemodynamic responses to intravenous injection of PGI, (1.0 pg/kg). After indomethacin, PGI, still produced significant increases in CBF and decreases in LDCR. Before and after indomethacin, for instance, the increases of CBF induced by PGI, were 43 f 11 ml/min (133 f 24%) and 37 f 6 ml/min (117 f 17%) (all P > 0.05, compared with before indomethacin, Fig. 4 ). The changes in MAP, HR, LVSP and LV dP/dt induced by PGI, were not altered by indomethacin ( Table 2) .
The coronary vasodilation and the hemodynamic responses to NTG were not affected by indomethacin.
Effects of autonomic receptor blockade on the responses to ACh and PGIz
After administration of propranolol (1 mg/kg) and atropine (0.1 mg/kg), the changes in hemodynamics and coronary circulation are reported in Table 3 . The coronary vasodilation and hemodynamic responses to ACh were almost completely blocked. ACh (5 pg/kg) neither increased CBF (10 f 6.7%, P > 0.05) nor decreased LDCR (3.9 + 2.0%, P > 0.05, Fig. 3) . No significant changes occurred in MAP, HR, LVP and LV dP/dt to ACh after atropine. The blockade of the autonomic receptor also partially blunted the coronary vasodilation responses to PGI,. After /3-adrenergic and muscarinic blockade, PGI, (1.0 pg/kg) increased CBF by only 15 f 1.7 ml/min (49 f 8%, P < 0.05 compared with control), and reduced LDCR by 42 f 9% (P <: 0.05, compared with the control, Fig. 4) . However, the hemodynamic responses (except for HR) to PGI, were not attenuated by combined padrenergic and muscarinic blockage. After propranolol and atropine, PGI, decreased MAP by 87 f 13 mmHg, LVSP by 78 f 13 mmHg, :LV dP/dt by 766 f 169 mmHg/s. No change in HR occurred following injection of PGI,. Values are mean f s.e.m., n = 4. P < 0.05, compared with control. LV, left ventricular; CBF, coronary blood flow; LDCR, late diastolic coronary resistance.
Discussion
The most important finding in this study is that coronary vasodilation following intravenous administration of PGI, is partially mediated by a NO-dependent mechanism. Tbis conclusion is supported by the observation that intravenous administration of NLA, a competitive inhibitor of NO synthase, partially attenuated the coronary vasodilation induced by PGI, in the conscious dog. These results indicate that two components are involved in the mechanisms of the coronary vasodilation induced by PGI,: one is its direct vasodilatory action; another is a vagal reflex action which is mediated by nitric oxide.
In the late 197Os, it was reported that PGI, resulted in relaxation of the coeliac and mesenteric arteries of rabbit IS] and the bovine coronary arteries [9] . Since then, a number of experiments have documented the effects of PGI, on the hemodynamics and the coronary circulation in anesthetized dogs [12] [13] [14] [15] [16] 231 , in rats [ 11,241 and in patients with angina pectoris 125,261. In the present experiment, intravenous injection of PGI, caused dose-dependent increases in coronary blood flow and decreases in late diastolic coronary resistance, which were consistent with our data and those of others. We further observed that the coronary vasodilation induced by PGI, was attenuated to a similar degree after administration of NLA or atropine (128% vs. 55% and 112% vs. 49%), suggesting that in addition to the direct vasodilatory action of PGI,, an NO dependent mechanism may be involved in the coronary vasodilation induced by PGI,.
Recently, Koller et al. [27] reported that lower concentrations of NLA did not affect the dilation of skeletal muscles arterioles in response to arachidonic acid and PGE,, however, higher concentration (10e3 M) of NLA significantly blunted the dilation of arterioles in skeletal muscles in response to arachidonic acid and PGE,. They interpreted this finding to indicate that the action of NLA was nonspecific. Thus it is possible that the attenuated coronary vasodilation of PGI, by NLA in our study could be due to a nonspecific action of NLA. Our observation that NLA partially attenuated coronary vasodilation induced by PGI, is a specific action of NLA, as evidenced by the reversal of the inhibition of NLA by L-arginine, a specific substrate of NO synthase. Salvemini et al. [28] found that NO could activate cyclooxygenase enzymes in mouse macrophage cell, suggesting that NO directly interacted with cyclooxygenase. In our experiment, we used PGI,, which is an active metabolite of arachidonic acid, to cause coronary vasodilation which is independent of the activity of cyclooxygenase. Our results showed that indomethacin which completely blocked the coronary vascdilation and the hemodynamic changes in response to arachidonic acid, did not affect the coronary vasodilation and the hemodynamic changes in response to PGI,. The attenuated coronary vasodilation of PGI, by NLA was, therefore, not due to the decreased activity of cyclooxygenase, but due to another mechanism(s).
To assess the mechanism of attenuated coronary vasodilation of PGI, by NLA, we determined the effects of blockade of muscarinic receptor. Our results showed that the coronary vasodilation following administration of PGI, (1.0 pg/kg) was also partially attenuated by atropine. The extent of the attenuated coronary vasodilation of PGI, by atropine was not different from that by NLA (Fig. 41 , suggesting that the partially attenuated coronary vasodilation to PGI, by NLA was also mediated by a vagal reflex. In 1979, we [ 171 first indicated that PGI, elicited bradycardia in the anesthetized dog which was abolished by vagotomy and confirmed by others [14] . We further demonstrated in anesthetized dog that the intracardiac production of prostaglandins caused activation of cardiac chemical ventricular receptors. In that experiment, intracoronary injection of arachidonic acid (the precursor of PGI,) at doses that had no or only small effects on resting arterial pressure and heart rate resulted in significant bradycardia and hypotension. After vagotomy, the bradycardia and hypotension following intracoronary injection of PGI, were abolished [16] . The results of the present study in awake dogs in which atropine partially attenuated the coronary vasodilation induced by PGI, further demonstrate that the coronary vasodilation induced by PGI, was in part mediated by a vagal reflex. It was reported that PGD, resulted in NO-dependent relaxation of the strip of bovine coronary arteries in vitro [29] . The current study provides evidence that another metabolite of arachidonic acid is involved in NO-dependent vasodilation in vivo but through a reflex mechanism.
It is well known that coronary vascular response during carotid chemoreflex activation was mediated by vagal parasympathetic cholinergic fibers [30] . Our recent studies showed that the increases in coronary blood flow and decreases in the late diastolic coronary resistance during chemoreflex activation or vagal stimulation were significantly inhibited by NO synthesis inhibitor, NLA, suggesting that an NO mechanism mediates parasympathetic coronary vasodilation [ 181. More recently, we have shown that the classical Bezold-Jarisch reflex coronary vasodilation as described by Feigl [31] is also mediated by NO [19] . In the present study, we demonstrated that intravenous administration of PGI, also caused parasympathetic coronary vasodilation which was mediated by an NO-dependent mechanism. Both results support the hypothesis that NO plays an important role in all forms of parasympathetic coronary vasodilation.
In in vitro studies, ACh resulted in an endothelium-dependent coronary relaxation [32] . ACh presumably stimulates endothelial muscarinic receptors leading to production and release of NO [33] . In in vivo studies, ACh induced dose-dependent coronary vasodilation in dogs, which was significantly inhibited by NO synthesis in-hibitors [34-361. In this study, intravenous injections of ACh caused dose-dependent increases in coronary blood flow and decreases in late diastolic coronary resistance in conscious dogs. The coronary vasodilation induced by ACh was significantly attenuated by NLA, and blocked by atropine. Our results are consistent with others [34-361. Nitroglycerin causes direct vasodilation which is endothelium-independent. Our results showed that the coronary vasodilation induced by nitroglycerin was not affected by NLA, suggesting that the reactivity of the vascular smooth muscle in coronary blood vessels is not affected by NLA.
In summary, the results of our study demonstrate that the coronary vasodilation induced by PGI, was partially attenuated by NLA or au-opine, suggesting that coronary vasodilation induced by PGI, is due to two components: a direct coronary vasodilation and a vagal reflex. Activation of vagal efferents results in cholinergic coronary vasodilation mediated by NO and peripheral a-adrenergic withdrawal which is independent of NO. Our results further support the hypothesis that NO plays an important role in all forms of parasympathetic coronary vasodilation.
